INS and obesity disorder: Pharmacological interventions aimed at repolarising ATMs from M1 to M2 phenotypes, or at least attenuating M1-associated inflammatory actions, are significant for improving insulin sensitivity and ameliorating obesity-related metabolic complications [147,152].